Artificial liver: the effect of ACAC microencapsulated charcoal hemoperfusion on fulminant hepatic failure.
Control trials and statistical analysis were carried out to assess the effects of albumin-collodion microencapsulated activated charcoal (ACAC) hemoperfusion on fulminant hepatic coma. A rat model of galactosamine induced fulminant hepatic coma was used. Rats which did not recover died at 3.0+/-0.6 days after galactosamine injection. Those which survived this period recovered. Forty-eight hours after galactosamine injection, a test group of 21 rats were treated with 1 hour hemoperfusion and compared with an untreated group of 23 rats. 71.4% of the treated group survived as compared to 30.4% of the untreated rats. Statistical analysis (t test) shows a significant increase in recovery for the treated group (less than 0.01). Biochemical and histological results will be discussed.
D000418:Albumins; D000818:Animals; D001187:Artificial Organs; D002606:Charcoal; D003101:Collodion; D004195:Disease Models, Animal; D005688:Galactosamine / Q000009:adverse effects; D006464:Hemoperfusion / Q000295:instrumentation / Q000379:methods; D006501:Hepatic Encephalopathy / Q000139:chemically induced / Q000628:therapy*; D006801:Humans; D008099:Liver / Q000473:pathology; D008107:Liver Diseases / Q000473:pathology; D051381:Rats
D000418:Albumins; D002606:Charcoal; D005688:Galactosamine; D003101:Collodion